Sophia Genetics SA

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SOPHiA GENETICS excels in Q4 2022, eyes biopharma growth

SOPHiA GENETICS reported strong financial performance in Q4 2022 and full-year 2022, driven by revenue growth, strategic partnerships, and operational efficiency improvements.
The company's focus on oncology and rare diseases, along with its multimodal approach and commitment to customer satisfaction, positions it well for sustained growth and value creation.
While facing challenges in maintaining growth momentum and managing operational metrics, SOPHiA has significant opportunities for expansion, partnerships, and leveraging AI for platform enhancement.

Sophia Genetics reports strong Q1 performance and eyes pharma growth

Sophia Genetics delivered strong Q1 results with revenue growth and customer expansions.
The company's focus on innovation and strategic partnerships positions it well for future growth.
While facing macro challenges and seasonal variability, Sophia Genetics remains optimistic about revenue growth.
Pharma partnerships and global presence offer significant growth opportunities for the company.

Sophia Genetics reports robust Q2 growth and strategic partnerships

Sophia Genetics delivered strong Q2 results with revenue growth and improved operating loss, driven by customer expansion and high growth areas like HRD testing and liquid biopsy.
While facing financial challenges, the company is actively managing costs and pursuing opportunities in innovative initiatives like DEEP-Lung-IV and MRD testing applications.
With a focus on sustaining growth and profitability, Sophia Genetics aims to leverage its strengths in genomics analytics and strategic partnerships to capitalize on market opportunities.
Investor confidence is reinforced by the company's reiterated annual guidance and expectations of continued growth, positioning Sophia Genetics for future success.

Sophia Genetics reports strong Q3 growth and strategic partnerships

Sophia Genetics delivered robust Q3 results, showing growth in revenue, customer adoption, and strategic partnerships.
Despite challenges in operating losses and lack of 2024 guidance, the company remains focused on sustainable growth and profitability.
Opportunities in precision medicine applications, FDA oversight alignment, and strong sales metrics position Sophia Genetics for continued success.

SOPHiA GENETICS reports strong Q4 earnings, eyes global expansion

SOPHiA GENETICS showcased robust financial performance, operational efficiency, and strategic growth initiatives in Q4 2023.
The company's focus on innovation, global expansion, and customer acquisition positions it well for future growth and market leadership.
Challenges in financial management and technology adaptation require careful navigation for sustained profitability and market competitiveness.
Opportunities in product expansion, market penetration, and strategic partnerships offer avenues for continued revenue growth and market expansion.

SOPHiA GENETICS reports solid Q1 performance and strategic growth plans

SOPHiA GENETICS reported solid Q1 performance with revenue growth to $15.8 million, strong bookings, and new logos signed.
Despite challenges in setup times and biopharma delays impacting revenue slightly, the company maintains full-year revenue guidance and operational targets.
Opportunities lie in emerging sequencing platforms adoption, new clinical business bookings, and potential acquisitions for growth and market leadership.
Overall, SOPHiA's strategic actions, competitive strengths, and commitment to sustainable growth position the company for continued success and expansion.

SOPHiA Genetics addresses revenue challenges, eyes growth opportunities in genomics

SOPHiA Genetics navigated challenges in Q2 with a focus on strategic actions and new opportunities. Despite revenue setbacks, the company is optimistic about future growth drivers and market initiatives. The revised full-year revenue outlook reflects a commitment to cost management and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Insights from multimodal datasets on the platform fuel cancer research in Canada BOSTON and ROLLE, Switzerland , Jan. 8, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced a collaboration with Exactis Innovation, based in Montreal, Quebec, who will contribute to cancer research and data-driven decision-making through SOPHiA GENETICS' multimodal real-world data offering. Exactis Innovation is a non-profit network of hospital partners across Canada dedicated to improving cancer survivorship through the acceleration of data-driven decision-making.

Exactis Innovation and SOPHiA GENETICS Announce Collaboration on Multimodal Data Analytics

The Hospital will use SOPHiA GENETICS technology to streamline workflows and expedite research BOSTON and ROLLE, Switzerland , Dec. 21, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation is an expansion of its existing work with SOPHiA GENETICS.

Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid Disorders

BOSTON and ROLLE, Switzerland, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco.

SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference

World-class liquid biopsy testing will be available to SOPHiA GENETICS customers BOSTON and ROLLE, Switzerland , Dec. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced an expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy. The range of solutions, including MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions, will help progress oncology research and tumor mutation profiling.

SOPHiA GENETICS Announces Expanded Suite of Liquid Biopsy Offerings

Through the expanded relationship CHU de Nîmes will advance its research of rare and inherited diseases through pharmacogenomics BOSTON and ROLLE, Switzerland , Nov. 30, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France. The hospital system will use the SOPHiA DDM™ Platform to progress its pharmacogenomics research.

SOPHiA GENETICS Announces Expansion of Work with CHU de Nîmes

Largest health center in Italy uses SOPHiA DDM™ Platform on Microsoft Azure to expand data-driven medicine capabilities while ensuring accuracy and security BOSTON and ROLLE, Switzerland , Nov. 28, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with the Città della Salute e della Scienza di Torino located in Turin, Italy. The hospital, which used SOPHiA GENETICS after a public tender in 2021 to optimize workflows and support research in the areas of hereditary cancer, neurological disorders, solid tumors, hematology and rare disease, will further expand its usage of the SOPHiA DDM™ Platform to support research on homologous recombination repair (HRR) biomarkers that indicate treatment options for ovarian, prostate, breast and pancreatic cancers.

SOPHiA GENETICS Expands Relationship with Città della Salute e della Scienza di Torino

The SOPHiA DDM™ Platform used by IHG PAS to advance its research of male infertility BOSTON and ROLLE, Switzerland , Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform. IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.

The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2023 Results Conference Call November 7, 2023 8:00 AM ET Company Participants Katherine Bailon - Head, IR Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO and COO Conference Call Participants Yuko Oku - Morgan Stanley Kyle Boucher - TD Cowen Mark Massaro - BTIG Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today.

SOPHiA GENETICS SA (SOPH) Q3 2023 Earnings Call Transcript

OPKO Health

World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON and ELMWOOD PARK, N.J. and ROLLE, Switzerland , Nov. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite.

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

BOSTON and ROLLE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Revenue for the third quarter of 2023 was $16.3 million, representing year-over-year growth of 40% on a reported basis over the corresponding period of 2022; Constant currency year-over-year revenue growth excluding COVID-19-related revenues was 37%.

SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023

BOSTON and GENEVA, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal 2023 before U.S. markets open on Tuesday, November 7, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EST / 2:00 p.m. (14:00) CEST.

SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2023 on November 7, 2023

AstraZeneca

The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science BOSTON and ROLLE, Switzerland , Oct. 18, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in data-driven medicine today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca (LSE/STO/Nasdaq: AZN) to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide.

SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care

The hospital will use the SOPHiA DDM™ Platform to further its work with myeloid disorders and advance the development of precision medicine BOSTON and ROLLE, Switzerland , Sept. 29, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Shaare Zedek, the largest multi-disciplinary medical center in Jerusalem, is now live on the SOPHiA DDM™ Platform.

Shaare Zedek Medical Center Uses SOPHiA GENETICS to Advance Research of Myeloid Disorders

The SOPHiA DDM™ Platform will help Laboratorio Curie advance its research into BRCA gene mutations BOSTON and ROLLE, Switzerland , Sept. 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, has expanded its relationship with Laboratorio Curie, a leading laboratory located in the capital city of Paraguay.

Laboratorio Curie Expands Relationship with SOPHiA GENETICS

With the help of the SOPHiA DDM™ Platform, IRST has introduced a new diagnostic kit that will support data- driven treatment planning for a dvanced ovarian cancer BOSTON and ROLLE, Switzerland , Sept. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, is helping excel the use of precision medicine to treat advanced ovarian cancer.

SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform

The hospital is using the SOPHiA DDM™ Platform to advance the research of Homologous  Recombinati on Repair Mutated Cancers BOSTON and ROLLE, Switzerland , Aug. 30, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that CHU Bordeaux, a full-service hospital servicing the population of Bordeaux and the surrounding area, has completed implementation of the SOPHiA DDM™ Platform into its organization. The hospital will be using the SOPHiA GENETICS technology to help advance its research on homologous recombination repair (HRR) mutated cancers.

CHU Bordeaux is live on SOPHiA GENETICS

Gustave Roussy uses SOPHiA DDM™ Platform to empower confident, data-driven medicine in the fight against cancer BOSTON and ROLLE, Switzerland , Aug. 22, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe. With the expanded relationship SOPHiA GENETICS will now further support Gustave Roussy via the SOPHiA DDM™ Platform, which will provide expedited analysis and insights of genomic profiles.

SOPHiA GENETICS Expands Relationship with Gustave Roussy

The Hospital will use the SOPHiA DDM™ Platform to advance its research and diagnosis of blood cancers BOSTON and ROLLE, Switzerland , Aug. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that A.O.U. San Giovanni di Dio Ruggi d'Aragona is now utilizing the SOPHiA DDM™ Platform to advance its research and diagnosis of blood cancers, specifically Myeloma.

A.O.U. San Giovanni di Dio Ruggi d'Aragona Expands Usage of SOPHiA GENETICS DDM™ Platform

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Katherine Bailon - Head, Investor Relations Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - Chief Financial Officer and COO Conference Call Participants Edmund Tu - Morgan Stanley Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Vidyun Bais - BTIG Operator Hello, ladies and gentlemen. And thank you for joining SOPHiA GENETICS Second Quarter 2020 Earnings Call.

SOPHiA GENETICS SA (SOPH) Q2 2023 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.39 per share a year ago.

SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates

BOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Revenue for the second quarter of 2023 was $15.1 million, representing year-over-year growth of 29% on a reported basis over the corresponding period of 2022; Constant currency year-over-year revenue growth excluding COVID-19-related revenues was 30%.

SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023

The School of Medicine will use the SOPHiA DDM™ Platform to expand its hematologic testing program for blood cancers BOSTON and ROLLE, Switzerland , Aug. 8, 2023  /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Tulane University School of Medicine in New Orleans, Louisiana is live on SOPHiA GENETICS technology. The 15th oldest medical school in the United States, Tulane University School of Medicine has a longstanding history of medical research and education and will leverage the SOPHiA DDM™ Platform to help scale its hematologic (blood) testing program to advance blood cancer research.

Tulane University School of Medicine Uses SOPHiA GENETICS to Advance Research of Blood Cancers

BOSTON and ROLLE, Switzerland , July 25, 2023 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the second quarter of fiscal 2023 before U.S. markets open on Tuesday, August 8, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2023 on August 8, 2023

CSM is using the SOPHiA DDM™ Platform to expand its next-generation sequencing (NGS) offerings BOSTON and ROLLE, Switzerland , July 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Gruppo Centro Servizi Medici (CSM), one of the largest centralized laboratories in Italy, is live on SOPHiA GENETICS technology. CSM has implemented the SOPHiA DDM™ Platform to help expand its current next-generation sequencing (NGS) offerings and advance its research of hereditary cancer and homologous recombination deficiency (HRD).

SOPHiA GENETICS Announces Gruppo Centro Servizi Medici (CSM) is Live on the SOPHiA DDM™ Platform

SOPHiA DDM™ Platform will bring next-generation sequencing in-house and help further research on hematologic malignancies BOSTON and ROLLE, Switzerland , July 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Centre Hospitalier de Bastia is live on the SOPHiA DDM™ Platform. Centre Hospitalier de Bastia, a general hospital located in the city of Bastia, on the French island of Corsica, is using the SOPHiA DDM™ Platform to introduce in-house next-generation sequencing (NGS), which will support their clinical oncology research and facilitate deeper insights into hematologic malignancies.

News for Sophia Genetics SA Stock (SOPH)